List of Qnasl drug patents

Qnasl is owned by Teva Branded Pharm.

Qnasl contains Beclomethasone Dipropionate.

Qnasl has a total of 2 drug patents out of which 0 drug patents have expired.

Qnasl was authorised for market use on 23 March, 2012.

Qnasl is available in aerosol, metered;nasal dosage forms.

The generics of Qnasl are possible to be released after 21 October, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter
Jan, 2027

(3 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 23 March, 2012

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in